Milestone Pharmaceuticals, a Phase 3 biotech developing therapies for heart rate conditions, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The Montreal, Canada-based company was founded in 2003 and plans to list on the Nasdaq under the symbol MIST. Milestone Pharmaceuticals filed confidentially on December 21, 2018. Jefferies, Cowen and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
